Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.56 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.56 |
| ▸ | POLA1 | P09884 | 1/20 | 0.50 |
| ▸ | CDK1 | P06493 | 9/20 | 0.48 |
| ▸ | CCNB1 | P14635 | 9/20 | 0.48 |
| ▸ | CDK2 | P24941 | 9/20 | 0.48 |
| ▸ | CCNA2 | P20248 | 8/20 | 0.48 |
| ▸ | CCNA1 | P78396 | 8/20 | 0.48 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.47 |
| ▸ | PI4KA | P42356 | 2/20 | 0.44 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.44 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.44 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | XDH | P47989 | 1/20 | 0.44 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.44 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | PNP | P00491 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL215054 | 1.00 | PDPK1 (0.56) | PDPK1GDAPOLA1CDK1CCNB1 | |
| SCHEMBL1074970 | 0.90 | POLA1 (0.57) | PDPK1GDAPOLA1CDK1CCNB1 | |
| SCHEMBL11222102 | 0.90 | PDPK1 (0.63) | PDPK1GDAPOLA1CDK1CCNB1 | |
| SCHEMBL28299226 | 0.89 | POLA1 (0.53) | PDPK1GDAPOLA1CDK1CCNB1 | |
| Fumaric Acid SCHEMBL28313166 | 0.88 | PDPK1 (0.44) | PDPK1GDAPOLA1CDK1CCNB1 | |
| SCHEMBL30610405 | 0.88 | CDK1 (0.53) | PDPK1GDAPOLA1CDK1CCNB1 | |
| SCHEMBL1924592 | 0.86 | PDPK1 (0.59) | PDPK1GDAPOLA1CDK1CCNB1 | |
| SCHEMBL29592683 | 0.86 | PDPK1 (0.59) | PDPK1GDAPOLA1CDK1CCNB1 | |
| Hydrochloric Acid SCHEMBL26629016 | 0.85 | CDK1 (0.51) | PDPK1GDAPOLA1CDK1CCNB1 | |
| Water SCHEMBL28083708 | 0.85 | PDPK1 (0.58) | PDPK1GDAPOLA1CDK1CCNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4746920-A1 | HEMATOPOIETIC CELL TARGETING CONJUGATES AND RELATED METHODS | Marrow Therapeutics, Inc. (US) | 2026-05-27 | — | — | EP | disclosed |
| CN-122095092-A | Inhibitor for inhibiting inhibin Beta E gene expression and application thereof | — | 2026-05-26 | — | — | CN | disclosed |
| CN-122095091-A | DsRNA for inhibiting LPA gene expression and application thereof | — | 2026-05-26 | — | — | CN | disclosed |
| WO-2026101887-A1 | NUCLEOTIDES WITH ALPHA-IMINO PHOSPHATE GROUPS AND BRIDGING SULFURS, AND METHODS OF SYNTHESIZING AND USING THE SAME | ILLUMINA, INC. (US) | 2026-05-15 | — | — | WO | disclosed |
| CN-122038302-A | Modified T cells and methods of making and using the same | 哈佛学院校长同事会 | 2026-05-15 | — | — | CN | disclosed |
| WO-2026089806-A2 | SAA1-TARGETED OLIGOMERIC COMPOUNDS, COMPOSITIONS AND USES | N-LOREM FOUNDATION (US) | 2026-04-30 | — | — | WO | disclosed |
| EP-4727955-A1 | CYSTEINE-SUBSTITUTED RSV-F PROTEINS | GlaxoSmithKline Biologicals S.A. (BE) | 2026-04-22 | — | — | EP | disclosed |
| WO-2026044046-A1 | PATTERNED MODIFIED OLIGONUCLEOTIDES FOR EXTENDED DURATION OF ACTION | IONIS PHARMACEUTICALS, INC. (US) | 2026-02-26 | — | — | WO | disclosed |
| WO-2026043966-A1 | COMPOUNDS AND METHODS FOR MODULATING ALPHA-SYNUCLEIN EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2026-02-26 | — | — | WO | disclosed |
| EP-4680275-A1 | RSV-F-ENCODING NUCLEIC ACIDS | GlaxoSmithKline Biologicals S.A. (BE) | 2026-01-21 | — | — | EP | disclosed |
| CN-109485676-B | Novel nucleoside reverse transcriptase inhibitors for antiviral use | 深圳市塔吉瑞生物医药有限公司 | 2022-07-15 | — | — | CN | disclosed |
| CN-105518146-B | Therapeutic uses of genome editing with CRISPR/Cas systems | 哈佛学院校长同事会 | 2022-07-15 | — | — | CN | disclosed |
| WO-2022150372-A1 | GUIDE RNA DESIGNS AND COMPLEXES FOR TYPE V CAS SYSTEMS | HORIZON DISCOVERY LTD. (GB) | 2022-07-14 | — | — | WO | disclosed |
| WO-2022150367-A1 | GUIDE RNA DESIGNS AND COMPLEXES FOR TRACR-LESS TYPE V CAS SYSTEMS | HORIZON DISCOVERY LTD. (GB) | 2022-07-14 | — | — | WO | disclosed |
| WO-2022150369-A1 | COMPOUNDS FOR THE TREATMENT OF BATTEN DISEASE | EXICURE OPERATING COMPANY (US) | 2022-07-14 | — | — | WO | disclosed |
| WO-2022122689-A1 | RNA MANUFACTURING | BioNTech SE (DE) | 2022-06-16 | — | — | WO | disclosed |
| WO-2022115539-A2 | MODULATING TRANSCRIPTIONAL CONDENSATES | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2022-06-02 | — | — | WO | disclosed |
| WO-2022094615-A1 | COMPOUNDS AND METHODS FOR INCREASED ANTISENSE ACTIVITY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-05-05 | — | — | WO | disclosed |
| CN-114404581-A | Cancer vaccine | 摩登纳特斯有限公司 | 2022-04-29 | — | — | CN | disclosed |
| EP-3976788-A1 | OLIGONUCLEOTIDE THERAPY FOR WOLMAN DISEASE AND CHOLESTERYL ESTER STORAGE DISEASE | Deep Genomics Incorporated (CA) | 2022-04-06 | — | — | EP | disclosed |